ZAVZPRET
Drug
PFIZER INC.
Total Payments
$10.7M
Transactions
3,786
Doctors
1,685
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $4.3M | 2,531 | 1,379 |
| 2023 | $6.4M | 1,255 | 409 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.1M | 1,496 | 94.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $360,979 | 145 | 3.4% |
| Food and Beverage | $84,439 | 2,045 | 0.8% |
| Consulting Fee | $70,670 | 15 | 0.7% |
| Travel and Lodging | $26,847 | 79 | 0.3% |
| Education | $23.16 | 6 | 0.0% |
Payments by Type
Research
$10.1M
1,496 transactions
General
$542,957
2,290 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $7.9M | 83 |
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $998,465 | 1 |
| RC ZAVEGEPANT CONCOMITANT USE WITH CGRPTARGETING PREVENTIVES | PFIZER INC. | $833,527 | 0 |
| A PHASE 1 SINGLE INTRANASAL DOSE OPENLABEL PHARMACOKINETIC STUDY OF ZAVEGEPANT IN HEALTHY LACTATING WOMEN | PFIZER INC. | $367,903 | 0 |
| AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 3ARM STUDY TO INVESTIGATE PAIN RESPONSE WITH INTRANASAL ZAVEGEPANT COMPARED WITH PLACEBO IN THE ACUTE TREATMENT OF MULTIPLE MIGRAINE ATTACKS IN ADULT PARTICIPANTS | PFIZER INC. | $53,000 | 0 |
| ZAVEGEPANT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $19,860 | 6 |
| ZAVZPRET CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,140 | 8 |
Top Doctors Receiving Payments for ZAVZPRET — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Neurology | Bronx, NY | $15,198 | 4 |
| , D.O | Family Medicine | Maitland, FL | $15,044 | 4 |
| , MD | Internal Medicine | Portland, OR | $14,808 | 5 |
| , M.D | Neurology | South Miami, FL | $14,401 | 6 |
| , MD | Specialist | Greensboro, NC | $14,081 | 5 |
| , MD | Family Medicine | Evansville, IN | $13,801 | 3 |
| , MD | Neurology | Waltham, MA | $13,639 | 3 |
| , M.D | Neurology | Richardson, TX | $12,991 | 9 |
| , D.O | Internal Medicine | Lake City, FL | $12,545 | 3 |
| , MD | Neurology | Oklahoma City, OK | $12,089 | 6 |
| , MD | Neurology | New York, NY | $11,922 | 5 |
| , M.D | Psychiatry | Cincinnati, OH | $11,538 | 6 |
| Narinder Saini | — | Springfield, OH | $11,083 | 1 |
| , M. D | Psychiatry | Jacksonville, FL | $10,818 | 6 |
| , MD | Internal Medicine | Chattanooga, TN | $10,791 | 7 |
| , MD | Psychiatry | Dallas, TX | $10,326 | 2 |
| , M. D | Neurology | Poughkeepsie, NY | $10,118 | 7 |
| , M.D | Neuromuscular Medicine | Austin, TX | $10,101 | 7 |
| , MD | Neurology | Washington, DC | $9,892 | 4 |
| , MD | Family Medicine | San Diego, CA | $9,260 | 3 |
| , D.O | Family Medicine | Cincinnati, OH | $9,215 | 2 |
| , MD | Neurology | Freehold, NJ | $9,132 | 9 |
| , M.D., MBA | Emergency Medicine | Wellesley, MA | $9,099 | 6 |
| , MD | Neurology | Chapel Hill, NC | $9,070 | 6 |
| , M.D., PH.D | Neurology | New York, NY | $8,915 | 9 |
Ad
Manufacturing Companies
- PFIZER INC. $9.7M
- BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $998,465
- PBG PUERTO RICO LLC $362.47
Product Information
- Type Drug
- Total Payments $10.7M
- Total Doctors 1,685
- Transactions 3,786
About ZAVZPRET
ZAVZPRET is a drug associated with $10.7M in payments to 1,685 healthcare providers, recorded across 3,786 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2023 to 2024. In 2024, $4.3M was paid across 2,531 transactions to 1,379 doctors.
The most common payment nature for ZAVZPRET is "Unspecified" ($10.1M, 94.9% of total).
ZAVZPRET is associated with 7 research studies, including "A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION" ($7.9M).